Drugmakers Build to Buy

Biogen Idec, Gelgene, and GlaxoSmithKine have signed deals with venture capitalists to develop startups that they can purchase later. Johnson & Johnson has taken a different approach to helping startups.

Apr 3, 2014 at 5:15PM

If you build it, they will buy it (especially if they told you what to build to begin with).

Quite a few big biotechs and pharmaceutical companies have called on venture capital firms to help them develop companies and compounds that they can turnaround and purchase once the drugs are developed further..

Biogen Idec (NASDAQ:BIIB) recently hooked up with Atlas Ventures, contributing $17 million to help fund the VC's development of Ataxion with an option to purchase the company after phase one work is complete.

Celgene (NASDAQ:CELG) teamed up with Versant Ventures on a biotech incubator called Blueline Biosciences to develop compounds coming out of academic research in Ontario, Canada.

GlaxoSmithKline (NYSE:GSK) signed a deal last year with Avalon Ventures to fund as many as 10 biotech start-ups with as much as $465 million. In exchange, Glaxo has first rights on buying the new companies.

Not every large company is building with the expressed intent to buy the start-up though. Johnson & Johnson's (NYSE:JNJ) Jansen Pharmaceuticals has a no-strings-attached incubator where start-ups pay rent and use shared equipment. While the incubator start-ups don't have to sign a deal to be purchased later, Johnson & Johnson hopes that being familiar with the companies working on its campus will help the health-care giant offer a fair price for the biotechs should they chose to sell.

In the video below, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss the trend and how it might be good for large drug companies, but bad for investors who prefer to invest in smaller biotechs.

Identifying innovation is the key
The key to getting market crushing returns is identifying companies that are breaking all the rules. Fool co-founder David Gardner and his team have a new free report that identifies six picks for ultimate growth. Click here now for your free access.

Brian Orelli has no position in any stocks mentioned. Max Macaluso owns shares of Celgene. The Motley Fool recommends Celgene and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers